CompletedPhase 2NCT03971643
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
Studying Classic pyoderma gangrenosum
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- InflaRx GmbH
- Principal Investigator
- Prof. Niels C. Riedemann, M.D., Ph.D.InflaRx GmbH
- Intervention
- vilobelimab(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2022
Study locations (10)
- InflaRx Site #07, Sacramento, California, United States
- InflaRx Site #08, Miami, Florida, United States
- InflaRx Site #03, Tampa, Florida, United States
- InflaRx Site #10, St Louis, Missouri, United States
- InflaRx Site #05, Columbus, Ohio, United States
- InflaRx Site #12, Hershey, Pennsylvania, United States
- InflaRx Site #09, Pittsburgh, Pennsylvania, United States
- InflaRx Site #01, Richmond Hill, Ontario, Canada
- InflaRx Site #21, Rzeszów, Poland
- InflaRx Site #20, Wroclaw, Poland
Collaborators
Innovaderm Research Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03971643 on ClinicalTrials.govOther trials for Classic pyoderma gangrenosum
Additional recruiting or active studies for the same condition.